151. Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
- Author
-
Arend von Stackelberg, Daniel Stachel, Roland Meisel, Ansgar Schulz, Thomas Klingebiel, Peter Lang, André Schrauder, Andre Willasch, Cornelia Eckert, Peter Bader, Martin Schrappe, Christina Peters, Hermann Kreyenberg, Ingo Müller, Ulrike Poetschger, Emilia Salzmann-Manrique, Julia Alten, and Michael H. Albert
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Time Factors ,Allogeneic transplantation ,Adolescent ,Kaplan-Meier Estimate ,Disease-Free Survival ,Young Adult ,Predictive Value of Tests ,Recurrence ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Cumulative incidence ,Prospective Studies ,Child ,Proportional Hazards Models ,Proportional hazards model ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Infant, Newborn ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Minimal residual disease ,Surgery ,Europe ,Transplantation ,Clinical trial ,Treatment Outcome ,medicine.anatomical_structure ,ROC Curve ,Area Under Curve ,Child, Preschool ,Multivariate Analysis ,Female ,Bone marrow ,Stem cell ,business - Abstract
Purpose To elucidate the impact of minimal residual disease (MRD) after allogeneic transplantation, the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster Stem Cell Transplantation Group (ALL-BFM-SCT) conducted a prospective clinical trial. Patients and Methods In the ALL-BFM-SCT 2003 trial, MRD was assessed in the bone marrow at days +30, +60, +90, +180, and +365 after transplantation in 113 patients with relapsed disease. Standardized quantification of MRD was performed according to the guidelines of the Euro-MRD Group. Results All patients showed a 3-year probability of event-free survival (pEFS) of 55%. The cumulative incidence rates of relapse and treatment-related mortality were 32% and 12%, respectively. The pEFS was 60% for patients who received their transplantations in second complete remission, 50% for patients in ≥ third complete remission, and 0% for patients not in remission (P = .015). At all time points, the level of MRD was inversely correlated with event-free survival (EFS; P < .004) and positively correlated with the cumulative incidence of relapse (P < .01). A multivariable Cox model was fitted for each time point, which showed that MRD ≥ 10−4 leukemic cells was consistently correlated with inferior EFS (P < .003). The accuracy of MRD measurements in predicting relapse was investigated with time-dependent receiver operating curves at days +30, +60, +90, and +180. From day +60 onward, the discriminatory power of MRD detection to predict the probability of relapse after 1, 3, 6, and 9 months was more than 96%, more than 87%, more than 71%, and more than 61%, respectively. Conclusion MRD after transplantation was a reliable marker for predicting impending relapses and could thus serve as the basis for pre-emptive therapy.
- Published
- 2015